Tukysa Side Effects
Generic name: tucatinib
Medically reviewed by Drugs.com. Last updated on Oct 4, 2021.
Note: This document contains side effect information about tucatinib. Some dosage forms listed on this page may not apply to the brand name Tukysa.
Applies to tucatinib: oral tablets.
Side effects include:
Adverse effects occurring in ≥20% of patients: Diarrhea, palmar-plantar erythrodysesthesia, nausea, fatigue, hepatotoxicity, vomiting, stomatitis, decreased appetite, abdominal pain, headache, anemia, rash.
Tucatinib (the active ingredient contained in Tukysa) increases Scr by inhibiting tubular secretion of creatinine. Elevated Scr concentrations are reversible following discontinuance of therapy. Use of alternative markers for renal function may be necessary if elevated Scr concentrations persist.
For Healthcare Professionals
Applies to tucatinib: oral tablet.
Very common (10% or more): Palmar-plantar erythrodysesthesia syndrome (63%), rash (e.g., rash maculopapular, rash, dermatitis acneiform, erythema, rash macular, rash papular, rash pustular, rash pruritic, rash erythematous, skin exfoliation, urticaria, dermatitis allergic, palmar erythema, plantar erythema, skin toxicity, dermatitis) (20%)[Ref]
Very common (10% or more): Diarrhea (81%), nausea (58%), vomiting (36%), stomatitis (e.g., stomatitis, oropharyngeal pain, oropharyngeal discomfort, mouth ulceration, oral pain, lip ulceration, glossodynia, tongue blistering, lip blister, oral dysesthesia, tongue ulceration, aphthous ulcer) (32%)[Ref]
Very common (10% or more): Hemoglobin decreased (59%), decreased phosphate (57%), anemia (e.g., anemia, hemoglobin decreased, normocytic anemia) (21%)[Ref]
Very common (10% or more): Bilirubin increased (47%), ALT increased (46%), AST increased (43%), hepatotoxicity (e.g., hyperbilirubinemia, blood bilirubin increased, bilirubin conjugated increased, alanine aminotransferase increased, transaminases increased, hepatotoxicity, aspartate aminotransferase increased, liver function test increased, liver injury, hepatocellular injury) (42%)[Ref]
Very common (10% or more): Arthralgia (15%)[Ref]
Very common (10% or more): Creatinine increased (33%)[Ref]
Very common (10% or more): Epistaxis
Frequently asked questions
- What’s the difference between tucatinib and neratinib?
- What's the mechanism of action for tucatinib?
More about Tukysa (tucatinib)
- Check interactions
- Pricing & coupons
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: HER2 inhibitors
- En español
Related treatment guides
1. "Product Information. Tukysa (tucatinib)." Seattle Genetics Inc (2020):
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.